Gilead Sciences (NASDAQ:GILD) PT Set at $88.00 by Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD) received a $88.00 price target from Cantor Fitzgerald in a research note issued to investors on Monday, TipRanks reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 31.50% from the company’s previous close.

Several other brokerages have also issued reports on GILD. Goldman Sachs Group set a $27.00 price target on Melco Resorts & Entertainment and gave the stock a “buy” rating in a report on Tuesday, May 28th. Oppenheimer set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, July 12th. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a report on Monday. Credit Suisse Group assumed coverage on Regeneron Pharmaceuticals in a report on Monday, May 20th. They issued a “neutral” rating and a $336.00 price target on the stock. Finally, Mizuho increased their price target on Iqvia from $145.00 to $150.00 and gave the stock a “neutral” rating in a report on Wednesday, June 19th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and seventeen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $80.99.

NASDAQ:GILD traded down $0.02 on Monday, hitting $66.92. The stock had a trading volume of 4,179,362 shares, compared to its average volume of 6,241,528. The company’s fifty day moving average price is $66.65. The company has a market cap of $85.45 billion, a P/E ratio of 10.88, a PEG ratio of 3.18 and a beta of 1.12. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62. Gilead Sciences has a 52 week low of $60.32 and a 52 week high of $79.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.48 earnings per share. As a group, analysts anticipate that Gilead Sciences will post 6.6 EPS for the current year.

In other news, Director John Francis Cogan sold 2,700 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $62.61, for a total value of $169,047.00. Following the completion of the sale, the director now directly owns 57,560 shares of the company’s stock, valued at $3,603,831.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,384 shares of company stock valued at $755,002. Company insiders own 0.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Cooper Financial Group increased its position in Gilead Sciences by 4.3% in the second quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 149 shares during the last quarter. Lenox Wealth Management Inc. boosted its holdings in shares of Gilead Sciences by 1.8% in the first quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock worth $589,000 after acquiring an additional 156 shares during the period. Vectors Research Management LLC boosted its holdings in shares of Gilead Sciences by 6.3% in the fourth quarter. Vectors Research Management LLC now owns 2,651 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 157 shares during the period. Creative Financial Designs Inc. ADV boosted its holdings in shares of Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares during the period. Finally, Rathbone Brothers plc boosted its holdings in shares of Gilead Sciences by 3.1% in the first quarter. Rathbone Brothers plc now owns 5,547 shares of the biopharmaceutical company’s stock worth $361,000 after acquiring an additional 167 shares during the period. 78.69% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: What is Liquidity?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.